cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Viking Therapeutics Inc
27 own
26 watching
Current Price
$9.96
$0.4
(4.18%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
763.82M
52-Week High
52-Week High
9.96
52-Week Low
52-Week Low
2.02
Average Volume
Average Volume
1.83M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization763.82M
icon52-Week High9.96
icon52-Week Low2.02
iconAverage Volume1.83M
iconDividend Yield--
iconP/E Ratio--
What does the Viking Therapeutics Inc do?
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program includes VK0612, an orally available drug candidate for the treatment of type 2 diabetes. The company is also developing VK5211, an orally available drug candidate, which is in a Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. In addition, it is developing VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis, as well as VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Read More
How much money does Viking Therapeutics Inc make?
News & Events about Viking Therapeutics Inc.
Benzinga
1day ago
read more...
PR Newswire
30days ago
Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) Viking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic...
PR Newswire
1month ago
Thinking about buying stock in AMC Entertainment, TAL Education, Omeros Corp, Acer Therapeutics, or Viking Therapeutics? Thinking about buying stock in AMC Entertainment, TAL Education, Omeros Corp, Acer Therapeutics, or Viking Therapeutics? PR Newswire NEW YORK, Dec. 23, 2022 NEW YORK, Dec. 23...
PR Newswire
1month ago
Thinking about buying stock in Core Scientific, AMC Entertainment, TAL Education, Rivian Automotive, or Viking Therapeutics? Thinking about buying stock in Core Scientific, AMC Entertainment, TAL Education, Rivian Automotive, or Viking Therapeutics? PR Newswire NEW YORK, Dec. 22, 2022 NEW YORK...
PR Newswire
1month ago
Thinking about buying stock in 180 Life Sciences, Viking Therapeutics, Camber Energy, New Oriental Education & Tech, or Rigel Pharmaceuticals? Thinking about buying stock in 180 Life Sciences, Viking Therapeutics, Camber Energy, New Oriental Education & Tech, or Rigel...
Frequently Asked Questions
Frequently Asked Questions
What is Viking Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Viking Therapeutics Inc shares?
plus_minus_icon
How can I buy Viking Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Viking Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Viking Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Viking Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Viking Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Viking Therapeutics Inc?
plus_minus_icon
What percentage is Viking Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Viking Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$9.96
$0.4
(4.18%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00